SYK
STRYKER CORP
Healthcare • CIK: 0000310764
Loading...
Market Cap
$141.18B
P/E (TTM)
47.9x
Rev Growth (TTM)
+11.0%
Net Margin (TTM)
12.1%
FCF Yield (TTM)
2.9%
FCF Margin (TTM)
16.7%
Cash Flow Health
Free Cash Flow8/8 positive
TTM$4.1B
Q3 '25
$1.4B+46%
Q2 '25
$928M+631%
FCF Margin
TTM16.7%
Q3 '2522.3%+45%
Sector: 5.8%Top 25%
OCF Margin19.8%
OCF/NI1.64x
CapEx Coverage6.4x
FCF Yield2.9%
FCF Growth (2Y)+26%
Cash Conversion Cycle
272 days
DSO: 58+DIO: 213−DPO: 0
Capital Allocation & Returns
Growth Focused
Total Shareholder YieldEst.
Est.0.9%
Div Yield0.9%
+Est. Buyback1.2%
Prioritizing reinvestment over distributions
Dividend & Payout Metrics
Dividend Yield (TTM)0.9%
FCF Payout Ratio31.5%
Free Cash Flow (TTM)$4.1B
Capital Return / FCF31.1%
Est. Dividends Paid (TTM)$1.3B
Estimated: Buyback data estimated from FCF. Actual repurchase data not available for this company.
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
9.6%
Stable
-0.3% YoY-5.1%
P25MedianP75
75th pctl (med: 0.1%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
13.3%
8Q: 15.8%
Asset Turnover
0.54x
8Q: 0.53x
Leverage (1+D/E)
–
Asset & CapEx Efficiency
Fixed Asset Turn
6.84x
8Q:6.63x
-30.5%
Invested Cap Turn
0.72x
8Q:0.73x
-11.7%
CapEx Intensity
2.2%
8Q:2.1%
CapEx/Depreciation
0.51x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $24.4B | $6.1B↑0.6% | $6.0B↑2.7% | $5.9B↓8.9% | $6.4B↑17.1% | $5.5B↑1.3% | $5.4B↑3.4% | $5.2B↓9.8% | $5.8B |
Operating Income | $3.7B | $1.1B↑2.0% | $1.1B↑33.0% | $837.0M↑44.1% | $581.0M↓46.5% | $1.1B↑3.2% | $1.1B↑8.1% | $972.0M↓22.7% | $1.3B |
Net Income | $2.9B | $859.0M↓2.8% | $884.0M↑35.2% | $654.0M↑19.8% | $546.0M↓34.5% | $834.0M↑1.1% | $825.0M↑4.7% | $788.0M↓31.1% | $1.1B |
Operating Cash Flow | $4.8B | $1.5B↑38.6% | $1.1B↑344.4% | $250.0M↓87.1% | $1.9B↑31.0% | $1.5B↑132.9% | $633.0M↑210.3% | $204.0M↓86.6% | $1.5B |
Free Cash Flow | $4.1B | $1.4B↑45.8% | $928.0M↑630.7% | $127.0M↓92.4% | $1.7B↑27.7% | $1.3B↑171.1% | $481.0M↑1200.0% | $37.0M↓97.3% | $1.4B |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
47.9x
Volatile
8Q: 168.1x+5922%
Multiple expansion without fundamental improvement
High PEG ratio (4.4x) suggests expensive for growth
Valuation Lenses
Earnings
47.9x
vs – sector
Cash Flow
3.1x
EV/FCF vs –
Growth-Adj
4.4xPEG
Expensive for growth
Quality-Adj
5.0P/E per %ROIC
ROIC: 9.6%
Shareholder Returns
Dividend
0.9%
Buyback
–
Total Yield
0.9%
Market Cap$141.18B
EV–
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
75/100
High Quality
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)
–
8Q:–
Return on Invested Capital (ROIC)Top 25%
9.6%
8Q:–
-5.1%
vs Sector:0.1%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 13.3%
Asset Turnover: 0.54x
Earnings Quality
Cash Conversion
1.64x
OCF / Net Income ✓
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin64.0%
Capital Efficiency
Invested Capital Turnover0.72x
Working Capital
Cash Conversion Cycle272 days
Growth Quality & Momentum
Moderate Growth
Growth Quality Score
71/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
11.0%
OpInc Growth YoY
4.6%
EPS Growth YoY
-18.4%
FCF 3Y CAGR
26.4%
Growth Quality Analysis
✓Efficient Growth: Free cash flow growing faster than revenue
✓Sustainability Index: 7.5/10 - Highly sustainable growth
Margin Quality & Sustainability
Low Quality
Profitability Cascade
Gross
64.0%
Operating
15.0%
Above Avg in sector
Net
12.1%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
+4.6 pts
FCF: 16.7% | Net: 12.1%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Net Debt / EBITDA
–Net Debt: $13.25B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
–x
Balance sheet risk & solvency analysis